Alexandria, VA – June 14, 2023 – The Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of health technology assessment (HTA) in healthcare, today announced the release of its proceedings report from the 2023 IVI 4th Annual Methods Summit, Rewriting the Playbook on Health Technology Assessment: Equity and Economic Impacts on Patients and Families.
The 2023 IVI 4th Annual Methods Summit was a two-day hybrid event that took place on March 13-14 in Washington, D.C. and convened more than 200 participants and thought leaders from across the healthcare ecosystem in facilitated panel discussions. The forum showcased multi-stakeholder perspectives on the “status quo” of how innovations in health technologies are being considered in decision-making, and opportunities and challenges that innovations in biopharmaceutical, digital, diagnostic, and delivery arenas for the science and practice of HTA.
“We’ve heard clearly that the inadequacies of data cannot stop us from working with intention to embed equity in both the processes and methods of HTA. We also heard that economic impacts on patients and families are significant and extend well beyond what we currently measure in research,” said Jennifer Bright, IVI’s chief strategy and engagement officer. “It will take action by everyone to begin the cycle of change needed to improve our understanding and measurement of value.”
Seven key themes emerged from the Summit:
- Pursuing fundamental change
- Shifting to shared power with patients and caregivers
- Prioritizing redefining data
- Using a range of (mixed) methods
- Practicing transparent, accessible communication
- Emphasizing shared learning and continuous improvement
- Establishing clear accountability
The proceedings report and key themes offer guidance on specific steps stakeholders can take to incorporate patient and family perspectives into healthcare decision-making.
The 2023 IVI 4th Annual Methods Summit was supported by contributions from PhRMA, Janssen Scientific Affairs, and Alexion Pharmaceuticals, and is partially funded through a Patient-Centered Outcomes Research Institute® (PCORI®) Eugene Washington PCORI Engagement Award (EASCS-24274). IVI general funds, which represent dues from diverse membership, also support this work.
The Innovation and Value Initiative (IVI) is a 501(c)(3) tax-exempt, non-profit research organization dedicated to advancing the science and improving the practice of health technology assessment through development of novel methods and the creation and application of enhanced health technology assessment models to support local decision-making needs in healthcare.
Contact: Smita Sanwardeker
E-Mail: [email protected]